Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.
Feature|Articles|August 13, 2026
- Pharmaceutical Executive: August 2026
- Volume 46
- Issue 6
2026 Emerging Pharma Leaders
Author(s)Mike Hollan
Listen
0:00 / 0:00
From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.
Advertisement
Follow the links below to read about each selection:
(In alphabetical order)
* These five selections were chosen from a pool of nominations evaluated by the Pharmaceutical Executive Editorial staff. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with those executives inhabiting key “C-suite” functions.
Articles in this issue
about 1 month ago
Pharmaceutical Executive: August 2026 Interactive Digital Editionabout 1 month ago
More Than Titlesabout 1 month ago
2026 Pharm Exec Top 50 Companiesabout 1 month ago
Making the Smart Career Movesabout 1 month ago
Two Decades of Technology Transformation in Pharmaabout 1 month ago
Finding the Universal Truth in a Drug's Storyabout 1 month ago
Preventing Cardiovascular Disease Through Mission-Driven Leadershipabout 1 month ago
What C-Suite Readiness Really RequiresAdvertisement
Related to this article
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Cellectis is pivoting from allogeneic CAR-T development to become an in vivo gene editing company, discontinuing its lasme-cel and eti-cel programs.
A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.
The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.
Novartis shareholders share deepened trust issues around the company's dealmaking strategy.
As leaders, we must evaluate solutions to fragmentation by asking
the right questions.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
The Battle to Own the GLP-1 Patient Journey
3
Pharmaceutical Executive Daily: FDA Approves Fayuvi
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5